BioCurex, Inc.(fka BOCX)

[HALF FULL GLASS]

Does This look Familiar?

This is a part of Abbott's recent Patent Application.

0163] where the "factor" is an integer (such as 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, etc.) and the "specificity" is a chosen value that is less than or equal to 1. The magnitude of "factor" increases for markers having. improved clinical performance, such as, but not limited to, higher AUC values, relatively small standard deviations, high specificity or sensitivity or low DFI. Thereupon, the measurement of one marker can be converted into as many or as few scores as desired. This method is based on the Receiver Operator Characteristic curve which reflects the marker/test performance in the population of interest. The ROC curve is the plot of the true positive rate (sensitivity) of a test against the false positive rate (1-specificity) of the test. Each point on the curve represents a single value of the feature/test (marker) being measured. Therefore, some values will have a low false positive rate in the population of interest (namely, subjects at risk of developing lung cancer) while other values of the feature will have high false positive rates in that population. This method provides higher scores for feature values (namely, biomarkers or biometric parameters) that have low false positive rates (thereby having high specificity) for the population of subjects of interest. The method involves choosing desired levels of false positivity (1-specificity) below which the test will result in an increased score. In other words, markers that are highly specific are given a greater score or a greater range of scores than markers that are less specific.

Following is Biocurex's recent news.

The first presentation entitled "CHEMILUMINESCENT ASSAY (CIA) FOR THE RECEPTOR OF ALPHA FETOPROTEIN (RECAF) TO SEPARATE CANCER FROM NORMAL SERA" demonstrates the results obtained with the assay format used in several automated instruments including the Abbott Architect(tm). 68 breast, gastric and other types of cancers were compared to 52 normal patients and the AUC(1) scoring obtained was 0.954 (a perfect discrimination between cancer and normal samples has a score of 1.0). Similar results were independently obtained in our Licensee's facility for prostate cancer samples.

The second study was done in collaboration with our Licensee and the University of Munich to determine the best type of specimen collecting tube for RECAF testing in a clinical laboratory environment

it is always necessary before the commercialization of a serum test to find out which tubes are chemically compatible. The results presented indicate that the RECAF assay is compatible with the most commonly used serum collection tube types.



http://72.14.205.104/search?q=cache:fe6kAbQ_vLcJ:www.freepatentsonline.com/20070178504.html+LIST+OF+ABBOTT+INTERNAL+CANCER+RECAF+TRIAL&hl=en&ct=clnk&cd=10&gl=us&ie=UTF-8
http://app.quotemedia.com/quotetools/popups/story.jsp